“Science and Technology Innovation Board Daily”, Feb. 20 (Reporter Li Mingming) Recently, Beijing Ainos Technology Co., Ltd. (hereinafter referred to as “Ainos Technology”) announced the completion of the C+ round of financing. The investors in this round are Yingchuan Capital and Huaxia Intelligence. This round of financing will be used for research on the application of artificial intelligence technology in the fields of eye health and school health informatization.

According to public information, Enos Technology was founded in Beijing in 2016 with a registered capital of 13.33 million yuan. Tan Guokai, the legal representative and executive director, holds 49.5% of the shares. It is one of the innovative enterprises in the field of eye health and school health informatization in China.

In 2019, Enos Technology and Peking University jointly established the “Peking University Medical School of Ophthalmology and Optometry Joint Laboratory”. Its self-developed “Children and Adolescent Vision and Common Disease Surveillance and Early Warning System” was classified as a “Health Technology” by the National Health and Health Commission.

An investor in the pharmaceutical sector analyzed to the “Science and Technology Innovation Board Daily” reporter that the application of artificial intelligence in the field of eye health is already quite mature. Among them, the most common is AI-assisted diagnosis. At the application level, machine learning algorithms can be used to analyze eye images to assist doctors in early diagnosis of diseases. Enos Technology has excellent technology in terms of information systems for myopia screening, but overall it is still far from advanced international manufacturers. Its main customers include the National Center for Disease Control and Prevention, the Beijing Center for Disease Control and Prevention, etc., and the customer base and market are relatively stable.

According to data from the Financial Association Venture Capital Connect - Zhizhong, since its establishment, Enos Technology has experienced a total of four rounds of financing: Series A financing began in June 2016, with an investment amount of RMB 4 million, not disclosed by the investor; Series B financing in January 2018, with an investment amount of RMB 20 million, not disclosed by the investor; Series C financing began in May 2019, with Donghua Software as the investor; the fourth round of C+ financing is now. Both investors are investment institutions in Beijing.

Beijing Yingchuan Capital, one of the current investors, was established in 2016 and is mainly engaged in investment management, project investment, and asset management. Major investment projects include Zhongneng Jinshi Energy, Medical Health, and Zhongnan Intellectual Property Co., Ltd.

Another investor, Beijing Huaxia Zhixun Technology Co., Ltd., specializes in basic software, application software, computer systems, and data processing. Major investment projects include Guorui Technology, Military Electronics, etc.

As to why Ainos was able to obtain financing this time, Tan Guokai, the company's legal representative, told the “Science and Technology Innovation Board Daily” reporter that Enos Technology has more than 40 intellectual property rights for digital technology related to eye health screening. The company's “informatization platform for monitoring, early warning and intervention for children and young people's eyesight and common diseases” currently has a high market share in the field of eye health screening and informatization for monitoring common diseases among students.

In addition, regarding the previous round of financing, Tan Guokai also said that the investor Donghua Software can empower the company in terms of technological innovation, business innovation, and channel development, and that Agnos has vertical technology application scenarios in the field of eye health. **